These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26931279)

  • 1. Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study.
    Dempster DW; Roschger P; Misof BM; Zhou H; Paschalis EP; Alam J; Ruff VA; Klaushofer K; Taylor KA
    J Bone Miner Res; 2016 Aug; 31(8):1527-35. PubMed ID: 26931279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao SD; Miller PD; Woodson GC; Lindsay R; Binkley N; Alam J; Ruff VA; Gallagher ER; Taylor KA
    J Bone Miner Res; 2016 Jul; 31(7):1429-39. PubMed ID: 26841258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study.
    Dempster DW; Zhou H; Ruff VA; Melby TE; Alam J; Taylor KA
    J Bone Miner Res; 2018 Apr; 33(4):627-633. PubMed ID: 29194749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao DS; Miller PD; Woodson GC; Lindsay R; Binkley N; Wan X; Ruff VA; Janos B; Taylor KA
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2799-808. PubMed ID: 22701017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.
    Misof BM; Roschger P; Gabriel D; Paschalis EP; Eriksen EF; Recker RR; Gasser JA; Klaushofer K
    J Bone Miner Res; 2013 Mar; 28(3):442-8. PubMed ID: 23044788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineral and organic matrix composition at bone forming surfaces in postmenopausal women with osteoporosis treated with either teriparatide or zoledronic acid.
    Paschalis EP; Dempster DW; Gamsjaeger S; Rokidi S; Hassler N; Brozek W; Chan-Diehl FW; Klaushofer K; Taylor KA
    Bone; 2021 Apr; 145():115848. PubMed ID: 33453443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study.
    Misof BM; Patsch JM; Roschger P; Muschitz C; Gamsjaeger S; Paschalis EP; Prokop E; Klaushofer K; Pietschmann P; Resch H
    J Bone Miner Res; 2014 Feb; 29(2):440-9. PubMed ID: 23832525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early effects of zoledronic acid and teriparatide on bone microarchitecture, remodeling and collagen crosslinks: comparison between iliac crest and lumbar vertebra in ewes.
    Portero-Muzy NR; Chavassieux PM; Bouxsein ML; Gineyts E; Garnero P; Chapurlat RD
    Bone; 2012 Oct; 51(4):714-9. PubMed ID: 22796591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
    Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.
    Dempster DW; Cosman F; Zhou H; Nieves JW; Bostrom M; Lindsay R
    J Bone Miner Res; 2016 Aug; 31(8):1518-26. PubMed ID: 26916877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques.
    Paschalis EP; Krege JH; Gamsjaeger S; Eriksen EF; Burr DB; Disch DP; Stepan JJ; Fahrleitner-Pammer A; Klaushofer K; Marin F; Pavo I
    J Bone Miner Res; 2018 Dec; 33(12):2230-2235. PubMed ID: 30102789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Teriparatide and Ibandronate on Cortical Bone in New Zealand White Rabbits: A HR-QCT Study.
    Iwamoto J; Seki A; Nango N
    Calcif Tissue Int; 2016 Nov; 99(5):535-542. PubMed ID: 27465620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution.
    Brennan MA; Gleeson JP; O'Brien FJ; McNamara LM
    J Mech Behav Biomed Mater; 2014 Jan; 29():161-70. PubMed ID: 24090875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients.
    Misof BM; Roschger P; Zhou H; Nieves JW; Bostrom M; Cosman F; Lindsay R; Klaushofer K; Dempster DW
    Bone Rep; 2020 Jun; 12():100253. PubMed ID: 32215284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study.
    Misof BM; Roschger P; Blouin S; Recker R; Klaushofer K
    Osteoporos Int; 2016 May; 27(5):1795-803. PubMed ID: 26650378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Daily Teriparatide versus One-Time Annually Zoledronic Acid Administration After Transforaminal Lumbar Interbody Fusion in Osteoporotic Patients.
    Wang Z; Zhuang C; Chen W; Li Z; Li J; Lin H; Dong J
    Clin Interv Aging; 2021; 16():1789-1799. PubMed ID: 34934310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats.
    Shimizu T; Tanaka T; Kobayashi T; Kudo I; Nakatsugawa M; Takakura A; Takao-Kawabata R; Ishizuya T
    Bone Rep; 2017 Dec; 7():70-82. PubMed ID: 28948197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
    J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.